[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Geneva\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":686},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,54,83,106,134,162,188,216,250,274,301,327,358,386,406,430,456,478,506,530,552,579,604,632,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100606268","hypnosis-on-breathlessness-mastery-in-patients-with-persistent-dyspnea-100606268",false,"NCT07173348","Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea","Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial","HYPNEA","Inclusion Criteria:\n\n* Patients aged ≥ 18 years and\n* Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and\n* Dyspnea stage NYHA ≥ II or mMRC ≥ 2\n\nExclusion Criteria:\n\n* Have had hypnosis treatment in the last 12 months\n* Have an estimated life expectancy of less than 6 months\n* Have participated in pulmonary rehabilitation in the last 6 months\n* Have been hospitalised in the last month (30 days)\n* Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks)\n* Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.)\n* Are not eligible for a hypnosis session due to a psychiatric disorder","ALL","18 Years",{"count":21,"type":22},82,"ESTIMATED","INTERVENTIONAL",[25],"NA","Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea.\n\nThe effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects.\n\nOur aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).",[28,29,30,31,32],"Cancer (With or Without Metastasis)","Interstitial Lung Disease (ILD)","Chronic Heart Failure (CHF)","COPD","Dyspnea",[34,35,36,37,38,39,40],"Hypnosis","Persistant dyspnea","Cancer with metastasis","Chronic Obstructive Pulmonary Disease","Interstitial Lung Disease","Chronic Heart Failure","Palliative Care","RECRUITING","2026-06-05",{"date":44,"type":45},"2026-06-08","ACTUAL",{"date":47,"type":45},"2026-04-01",{"date":49,"type":22},"2028-04-01",{"name":51,"class":52},"University Hospital, Geneva","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":82},"100570666","hybrid-percutaneous-coronary-intervention-combining-a-bioresorbable-scaffold-with-drug-coated-balloons-versus-a-conventional-drug-eluting-stent-based-strategy-in-patients-with-long-and-diffuse-coronary-artery-disease-100570666","NCT06710210","Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease","Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease: the BIOHYBRID Randomized Pilot Trial","BIOHYBRID","Inclusion criteria:\n\n* Clinical inclusion criteria\n\n  1. Participant is ≥18 years.\n  2. Participant has provided written informed consent as approved by the independent Ethical Committee (EC) or Institutional Review Board (IRB) of the respective participating centre prior to any study-related procedure.\n  3. Participant is eligible for PCI according to the ESC guidelines (4, 5) .\n  4. Participant is hemodynamically stable.\n  5. Participant with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS): unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or stabilized ST-segment elevation myocardial infarction (STEMI).\n\n  5a. Participants with STEMI are eligible for the treatment of non-culprit coronary lesions, if participant consent occurs ≥72 hours after successful primary PCI of the culprit STEMI lesion.\n\n  5b. Target lesion(s) to be treated are not located in the STEMI culprit vessel(s) and are not STEMI culprit lesion(s).\n\n  6\\. Participant is eligible for dual antiplatelet therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, or ticagrelor for ≥6 months.\n\n  7\\. Participant is willing to participate and able to comply with the protocol requirements for the duration of the study, including completion of study visits and control coronary angiogram at 12 months.\n\nAngiographic inclusion criteria 8. Target lesion length is \\>40 mm according to operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA), Intravascular Ultrasound (IVUS), or Optical Coherence Tomography (OCT).\n\n9\\. Target vessel has a maximum reference diameter between 3.0-4.6 mm according to operator visual estimation, which may be assisted by QCA, IVUS, or OCT.\n\nNotes: The proximal segment, which has a larger vessel diameter, will be treated with one Freesolve scaffold, in accordance with the vessel diameter range specified in the IFU. The distal segment, which naturally tapers to a smaller diameter, can be treated with one or more Pantera Lux DCB, in accordance with the vessel diameter range specified in the IFU.\n\n10\\. Target lesion with a baseline (pre-PCI) Thrombolysis In Myocardial Infarction (TIMI) flow ≥1.\n\nExclusion criteria:\n\nClinical exclusion criteria\n\n1. Participant has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy or intolerance to aspirin, P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel), both heparin and bivalirudin, any of the following DES or bioresorbable scaffold component (magnesium, aluminium, tantalum, poly-L-lactide, or sirolimus), or drug-coated balloon component (paclitaxel).\n2. Participant with STEMI \\\u003C72 hours prior to study index procedure. 12a: Participants with hemodynamically stable NSTEMI are eligible for study enrolment.\n3. Participant with prior PCI within the target vessel during the last 12 months prior to the study index procedure.\n4. Participant is on dialysis or has chronically impaired renal function defined as serum creatinine \\>2.5 mg\u002FdL or 221 μmol\u002FL.\n5. Participant is unable to adhere to DAPT for at least 6 months (e.g. planned surgery, dental surgical procedure, active bleeding disorders, active coagulopathy).\n6. Participant is on oral anticoagulation therapy (OAC) prior to index procedure unless DAPT plus OAC (i.e. triple therapy) can be maintained for a minimum of 1 month.\n7. Participant with life expectancy \\\u003C1 year.\n8. Participant is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study.\n9. Participant is currently participating or planning to participate in another interventional clinical trial, except for observational registries or previous enrolment into the current investigation.\n10. Participant unwilling or unable (e.g. physical or cognitive) to comply with study procedures, medication adherence and schedule.\n11. Contraindications and limitations of the medical devices as described in the instructions for use.\n12. Known or suspected non-compliance, drug or alcohol abuse.\n13. Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n14. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation.\n\n    Angiographic exclusion criteria\n15. Target vessel previously treated with a bare-metal stent or a drug-eluting stent and the target lesion is within 5 mm proximal or distal to the previously treated lesion.\n16. Target lesion is a chronic total occlusion.\n17. Target lesion is located in left main coronary artery, ostial left anterior descending artery, ostial left circumflex artery, or ostial right coronary artery (within 5.0 mm of the vessel origin).\n18. Target lesion is located in, or supplied by, an arterial or venous bypass graft.\n19. Target lesion with excessive tortuosity proximal to or within the lesion based on operator visual estimation, or heavily calcified target lesion which may be adequately prepared using a non-compliant and\u002For cutting\u002Fscoring balloon.\n20. Target lesion requires treatment with a device other than a non-compliant balloon and\u002For a modified (cutting\u002Fscoring) balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy).\n21. Target lesion involves a coronary bifurcation with a side branch with reference vessel diameter ≥2.0 mm that requires a two-device strategy after pre-dilatation.\n22. Presence of thrombus in the target vessel.\n23. Future planned staged PCI or coronary artery bypass graft surgery after the study PCI procedure.\n24. Target with unsuccessful lesion preparation, defined as the absence of residual stenosis ≥30%, TIMI flow grade \\\u003C3 following complete lesion preparation (6), type C to F coronary artery dissection according to the National Heart, Lung and Blood Institute (NHLBI) classification (7) (Appendix 2) and angiographic complications (e.g. distal embolization, or side branch closure).",{"count":63,"type":22},150,[25],"The primary objective of the study is to assess the safety and the efficacy of a hybrid percutaneous coronary intervention (PCI) strategy combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland) compared to a conventional DES-based PCI approach using \\>1 newer-generation drug-eluting stents (Orsiro Mission, Biotronik AG, Switzerland) for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI with respect to vessel-level absolute change in non-invasive angiography-derived fractional flow reserve (FFRangio, CathWorks, Newport Beach, USA) between post-index PCI and 12-month follow-up.\n\nBIOHYBRID is a coronary revascularization strategy study comparing two contemporary treatment approaches for patients with long and\u002For diffuse coronary artery lesions undergoing PCI.\n\nThe primary hypothesis of the study is that a hybrid PCI strategy using a 'leave nothing behind' or 'metal-free' approach that combines a bioresorbable magnesium scaffold and drug-coated balloons for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI is feasible.\n\nThe secondary hypothesis is that a hybrid PCI strategy combining a bioresorbable magnesium scaffold and drug-coated balloons is non-inferior to a conventional DES-based PCI approach using one or several DES for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI with respect to vessel-level absolute change in FFRangio (CathWorks, Newport Beach, USA) between post-index PCI and at 12 months of follow-up.",[67,68,69],"Coronary Artery Disease","Diffuse Coronary Artery Disease","Percutaneous Coronary Intervention (PCI)",[71,72,73,74,75],"Diffuse\u002Flong coronary artery disease","Percutaneous coronary intervention","Drug-eluting stents","Drug-coated balloons","Bioresorbable scaffold","2026-06-01",{"date":78,"type":45},"2026-06-02",{"date":47,"type":45},{"date":49,"type":22},{"name":51,"class":52},3,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":18,"minAge":91,"maxAge":19,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":53},"100484949","anhydroglucitol-in-children-with-type-1-diabetes-100484949","NCT05594706","Anhydroglucitol in Children With Type 1 Diabetes","Anhydroglucitol as a Measure of the Functional Beta-cell Mass in Children With Type 1 Diabetes - Pilot Study","Inclusion Criteria:\n\n* Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.\n* Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).\n* Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).\n* Patient willing to keep the same type of CGMS or FGM during the year of observation\n* Ability to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM\n* Patients changing the type of CGMS during the course of the study.",true,"2 Years",{"count":93,"type":22},60,"OBSERVATIONAL","The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.",[97],"Diabetes Mellitus, Type 1","2026-05-14",{"date":100,"type":45},"2026-05-18",{"date":102,"type":45},"2023-01-27",{"date":104,"type":22},"2026-12-31",{"name":51,"class":52},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":113,"minAge":19,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100603721","hyperbaric-oxygen-therapy-to-improve-autologous-fat-graft-intake-in-irradiated-breast-100603721","NCT07140198","Hyperbaric Oxygen Therapy to Improve Autologous Fat Graft Intake in Irradiated Breast","Prospective Study to Evaluate the Effectiveness of Hyperbaric Oxygen Therapy (HBOT) to Increase the Survival of Autologous Fat Transfer for Breast Reconstruction After Radiotherapy: A Randomized Controlled Phase II Cross-over Trial","Inclusion Criteria:\n\n* Adult (18 y.o. or more) female patients considered for lipofilling following breast reconstruction in an oncological setting which received radiation therapy on the affected breast.\n* Ability to provide informed consent, documented by signature\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unability to provide informed consent\n* Previous enrolment into the current investigation\n\nContra-indication to HBOT :\n\n* Anamnestically reported spontaneous pneumothorax\n* Status post-thoracotomy\n* Significant intra-pulmonary lesions (including emphysematous bullae)\n* Respiratory function disorders (both obstructive and restrictive syndromes)\n* Pregnancy\n* Major psychiatric disorders\n* Uncontrollable claustrophobic reaction\n* Seizures, even if treated and asymptomatic for some time\n* Status post-severe traumatic brain injury with neurological deficits and seizures\n* Decompensated heart failure\n* Recent myocardial infarction (\\\u003C6 months) or with persistent hemodynamic sequelae\n* Spastic coronary angina\n* Cardiac arrhythmias, atrioventricular block, Wolff-Parkinson-White syndrome, sinus node dysfunction, Lown-Ganong-Levine syndrome\n* Cardiac pacemakers with unknown pressure resistance\n* Severe bradycardia\n* Sinus ostium displacement (acute or chronic)\n* Displacement of the auditory canal entrance (acute or chronic)\n* Status post-tympanoplasty type I-III \\\u003C3 months\n* Acute febrile state\n* Optic neuritis\n* Unstabilized hyperthyroidism\n\nContra-indication to MRI :\n\n* Non-MRI-compatible pacemaker, cochlear implant, drug-infusion pump or neurostimulator.\n* Metallic foreign body in critical area (eye, brain, etc.)\n* Ferromagnetic vascular surgical clips of older generation, e.g., for intracranial aneurysm repair.","FEMALE",{"count":115,"type":22},16,[25],"The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) enhances fat graft survival in lipofilling procedures in irradiated breast cancer patients. The main questions it aims to answer are:\n\nDoes it improve fat graft survival ? Evaluate safety and tolerability of HBOT in this setting? Researchers will compare patient receiving HBOT to a control group without HBOT to see if.\n\nSixteen female patients will undergo two autologous fat grafting sessions: one with HBOT and one without, in a randomized sequence. Patients will undergo three MRI during the study to evaluate the fat retention rate.",[119,120,121],"Breast Reconstruction","Lipofilling","Hyperbaric Oxygen Therapy",[123,124,125,126],"breast reconstruction","Irradiation","hyperbaric oxygen therapy","lipofilling","2026-05-11",{"date":98,"type":45},{"date":130,"type":45},"2026-03-01",{"date":132,"type":22},"2028-12",{"name":51,"class":52},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":113,"minAge":4,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":53},"100573027","hormonal-management-of-heavy-menstrual-bleeding-in-adolescents-100573027","NCT06740929","Hormonal Management of Heavy Menstrual Bleeding in Adolescents","Hormonal Management of Heavy Menstrual Bleeding in Adolescents and Young Adults With and Without a Bleeding Disorder: a Prospective Observational Cohort Study","JAdoRE","Inclusion Criteria:\n\n* Adolescents and young adults aged \\\u003C 26yo\n* Presenting to the gynecology consultation at HUG\n* Diagnosed with heavy menstrual bleeding (PBAC \\> 100)\n* Willing to initiate a hormonal medication to manage heavy menstrual bleeding\n\nExclusion Criteria:\n\n* Pregnancy or planning to become pregnant during the study period\n* Already using hormonal medication for menstrual management and\u002For contraception\n* Known anatomical uterine pathology\n* Using anticoagulant or antiaggregant agents","25 Years",{"count":144,"type":22},163,"The goal of this study is to evaluate whether hormonal medications (such as contraceptive pill, patch, injectable progestins and hormonal intra-uterine device) have similar efficacy at managing heavy menstrual bleeding in adolescents with a bleeding disorder compared to those without. We also aim to assess the quality of life and hemoglobin and iron levels in this population.",[147,148],"Heavy Menstrual Bleeding","Bleeding Disorder",[150,151,152,153,154],"heavy menstrual bleeding","bleeding disorder","adolescent","contraception","menstrual management",{"date":156,"type":45},"2026-05-12",{"date":158,"type":45},"2024-12-17",{"date":160,"type":22},"2027-12",{"name":51,"class":52},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":113,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":53},"100556345","ablative-sbrt-in-elderly-bc-patients-100556345","NCT06523894","Ablative SBRT in Elderly BC Patients","EASE (brEAst Stereo Elderly): A Phase Ia\u002FIb Study of Stereotactic Ablative Irradiation as an Alternative to Surgery in Elderly and Comorbid Breast Cancer Subjects","EASE","Inclusion Criteria:\n\n1. Age over 70 years\n2. Histologically confirmed diagnosis of BC, any time before study enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.\n4. Patient considered inoperable in multidisciplinary board decision or refusing surgery. Main criteria determining inoperability are inability to receive general anesthesia after anesthetics and\u002For surgical evaluation. Criteria described in the statement of American Society of Anesthesiologists (ASA) {, #4699} and American College of Surgeons Surgical risk calculators {, #4695} are usually addressed in the multidisciplinary discussion (Appendix ).\n5. Presence of measurable disease in the breast, defined as a lesion that can be accurately measured in at least one dimension with imaging (ultrasound, CT or MRI). Disease in the axilla or internal mammary chain is allowed and will be treated at the discretion of the radiation oncologist. Regional disease is not considered in measurements of local response.\n6. Primary tumor accessible to SBRT, as defined by treating radiation oncologist.\n7. Neo-adjuvant systemic therapy is allowed.\n8. Tumor size in planning computed tomography (CT) permitting SBRT delivery. SBRT appropriateness is defined by the treating radiation oncologist.\n9. Multifocality (over two tumor foci within the same breast quadrant) is allowed, as long as the total treatment volumes remain suitable for SBRT, as defined by the treating radiation oncologist.\n10. Total tumor treatment volume\u002F whole breast volume ratio not exceeding 30%.\n11. Previous treatment for BC to the contralateral breast is allowed. Previous treatment to the same breast for other reason than BC is allowed.\n12. Capacity of patient to collaborate for SBRT delivery.\n13. Capacity of patient to understand and sign a written informed consent according to International Council for Harmonization (ICH)\u002FGood Clinical Practice (GCP) regulations before registration.\n\nExclusion Criteria:\n\n1. Prior surgery for the current diagnosis.\n2. Prior whole or partial breast irradiation to the involved breast.\n3. Absolute contraindication to RT, such as Li-Fraumeni syndrome.\n4. Current participation and receipt of study therapy or previous participation in a study of an investigational agent and receipt of study therapy or used an investigation device within 4 weeks of the first day of treatment.\n5. Not able to communicate meaningfully with investigator and site staff and\u002For incapable of discernment.\n6. Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.\n\n   \\-","70 Years",{"count":172,"type":22},36,[25],"Stereotactic body radiotherapy (SBRT) is a modern radiotherapy technique, through which extremely high doses of irradiation are delivered in a very precise manner, within a few fractions. SBRT is increasingly used into clinical practice because it can provide excellent local control, comparable to surgery, in many tumor locations, such as lung, liver or bone. Efforts to develop it for BC treatment are promising, as it is safe, convenient, and effective. To date, SBRT for BC has been developed as an alternative method of partial-breast irradiation (PBI) in the pre- or post-operative setting. Therefore, the doses tested are comparable to the conventional doses used with surgery although its potential as sole local treatment for BC remains unknown. Higher SBRT doses are expected to permit obtaining an ablative effect on tumor and be suitable as an alternative to surgery, but this hypothesis has yet to be tested.\n\nThe aim of the present study is to prove the feasibility of SBRT as an ablative treatment in early breast cancer (BC). The primary objective is to find the maximum tolerated dose of SBRT that can be safely administered in inoperable patients with BC, the majority of whom are elderly or oldest old.\n\nThe overall objective is to determine whether high precision, dose- and fractionation- adapted SBRT is feasible and safe in inoperable patients with BC. The dose and fractionation-adapted SBRT regimen permits to test feasibility in different tumor sizes.\n\nThe primary objective of this study is to establish the maximum tolerated dose (MTD) that can be delivered with a single or few (up to 5) fractions of SBRT in inoperable patients with BC.",[176],"Breast Cancer",[178,179,180],"radiotherapy","SBRT","inoperable","2026-05-05",{"date":127,"type":45},{"date":184,"type":45},"2025-03-25",{"date":186,"type":22},"2029-03-25",{"name":51,"class":52},{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":197,"studyType":94,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":53},"100636389","can-pre-operative-lean-mass-predict-weight-loss-after-roux-en-y-gastric-bypass-100636389","NCT07565051","Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?","FLAG","Inclusion Criteria:\n\n* Patients ≥ 18 years AND\n* Meeting inclusion criteria for RYGB (www.smob.ch): BMI ≥35 kg\u002Fm2, failure of weight-reducing programs over 2 years (for patients with a BMI ≥50 kg\u002Fm2, 1 year), understanding of the necessity to change the lifestyle and eating habits post-operatively, signed consent for lifelong post-operative follow-up in a recognized bariatric center AND\n* Scheduled RYGB at the HUG OR previous RYGB at the HUG with a present follow-up in Clinical Nutrition and dietetics at the HUG AND\n* Understanding French\n\nExclusion Criteria:\n\n* Inability or refusal to give consent.\n* Planification for another type of bariatric surgery than RYGB\n* Contra-indications to bariatric surgery as stated under www.smob.ch: insufficient nutritional knowledge in nutrition to lose weight, pregnancy, kidney failure (Creatinine ≥ 300 umol\u002Fl without dialysis, Crohn's disease, active cancer or remission \\\u003C 2 years, active psychiatric disease, substance abuse (alcohol, cannabis, opioids), absence of compliance, lack of understanding of the requirements and necessary lifestyle changes reported by physician or dietician.",{"count":196,"type":22},91,"5 Years","The goal of this observational study is to evaluate whether preoperative fat-free mass predicts post-operative weight loss in patients undergoing Roux-En-Y gastric bypass. The primary objective of this study is to evaluate whether preoperative fat-free mass predicts weight loss in the two years following RYGB.\n\nThe investigators will collect the following data, assessed as part of routine follow-up:\n\n* height, weight, hip and waist circumferences\n* body composition by bioimpedance analysis and dual energy-X-ray absorptiometry\n* Muscle strength and physical activity\n* Nutritional parameters: resting energy expenditure, eating behavior and digestive tolerance\", plasma micronutrient status. .\n* Cardiovascular risk factors: fasting glucose, blood levels of Hb1Ac, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure\n* Co-morbidities: joint pain and arthritis, sleep apnea, gastro-oesophageal reflux, metabolic dysfunction-associated fatty liver disease (MAFLD), cancer, stroke, heart attack.\n\nQuality of life: quality of life by the \"Bariatric Analysis and Reporting Outcome (BAROS) questionnaire\", symptoms of dumping syndrome by the \"Sigstad diagnostic score system\" Birthdate, birthweight and term of their children",[200],"Morbid Obesity Requiring Bariatric Surgery",[202,203,204,205,206,207],"obesity","gastric bypass","body composition","bone mineral density","handgrip strength","sarcopenic obesity","2026-05-04",{"date":210,"type":45},"2026-05-08",{"date":212,"type":45},"2025-08-18",{"date":214,"type":22},"2032-08-18",{"name":51,"class":52},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":234,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100613517","early-antibiotics-adaptation-in-severe-pneumoniathe-early-adapt-study-100613517","NCT07267624","EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)","EARLY Antibiotics aDaptation in Ventilator-Acquired-Pneumonia Treatment After Implementation of a Broad-Panel Respiratory Multiplex PCR Test: A Multicenter Randomized Control Trial Conducted In Swiss Intensive Care Units. The EARLY ADAPT Study.","EARLY ADAPT","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old)\n* Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours\n* Administration of antimicrobial therapy for suspected VAP at the time of inclusion.\n* Expected survival \\> 96 hours.\n\nExclusion Criteria:\n\n* Enrollment prior to the current trial\n* Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices.",{"count":225,"type":22},170,[25],"The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed ventilator-associated pneumonia, compared to standard diagnostic methods.\n\nAs secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.",[229,230,231,232,233],"VAP - Ventilator Associated Pneumonia","Antibiotic","Antibiotic Stewardship","Antibiotic Prescribing for Acute Respiratory-tract Infections","Intensive Care (ICU)",[235,236,237,238,239,240],"ventilator Associated Pneumonia (VAP)","antibiotic","PCR multiplex","intensive care","broad spectrum antibiotic","stewardship","NOT_YET_RECRUITING","2026-04-28",{"date":244,"type":45},"2026-04-29",{"date":42,"type":22},{"date":247,"type":22},"2028-06-30",{"name":51,"class":52},5,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":90,"sex":113,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":53},"100606251","the-impact-of-a-novel-gnrh-antagonist-with-add-back-therapy-for-treatment-of-uterine-fibroids-and-endometriosis-on-hemostasis-parameters-100606251","NCT07173127","The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters","The Effect of a Novel Combined Hormonal Treatment Containing a GnRH-antagonist for Uterine Fibroids and Endometriosis on Hemostasis Parameters: a Prospective Cohort Study","Inclusion Criteria:\n\n* Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Unable to speak and\u002For read French\n* Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate\n* Women not having given their consent to participate in the study",{"count":258,"type":22},30,[25],"Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and\u002For menstrual pelvic pain and abnormal uterine bleeding. The first-line management of these conditions relies on medical treatment. Hormonal treatment with contraceptive pill can be effective, although up to 30% of patients do not respond to this line of treatment. In this context, GnRH antagonists have been introduced. By suppressing ovulation, they inhibit the action of the gonadal axis and thus can reduce bleeding and pain associated with uterine fibroids and endometriosis. More recently, the GnRH antagonist known as Relugolix has been associated with a low-dose oestradiol and progesteron-line molecule, a medication known as Ryeqo. The goal of this type of treatment is to suppress ovulation while also minimizing symptôms which may derive from lack of oestrogen and progesterone in reproductive age women.\n\nWhile Ryeqo's efficacy has been proven by multiple large randomized controlled trials, its impact on blood coagulation has yet to be determined. Venous thromboembolism (VTE) is the main, potentially fatal, dleterious effect of oestrogen-containing hormonal treatmen, such as combined oral contraceptives (COC). Several epidemiological studies have found a 3-6 increase in the risk of VTE among women on COC. The thrombogenic risk can be assessed by measuring specific blood biomarkers, which are known to be correlated to the thrombogenic phenotype and allow an overview of the VTE risk prior to conducting large population-scale studies directly measuring the adverse event's prevalence.\n\nThe aim of this study is to document the effects of Ryeqo® on hemostasis parameters in order to estimate the risk of VTE associated with its employ. An improved understanding of the VTE risk associated with Ryeqo® will allow to adapt hormonal treatment based on each woman's personal risk profile.\n\nThe study will be explained to all women whose medical condition allows the prescription of Ryeqo. All women who give their consent to participate in the study will have a urinary pregnancy test and a blood sample drawn before beginning treatment with Ryeqo. A second visit will be scheduled at 3 months, throughout which a second blood sample will be drawn. A questionnaire including socio-demographic data and clinical symptoms will be completed both on the first and the second visit.",[262],"Uterine Fibroid",[264,265,266,267],"Uterine fibroids","Endometriosis","GnRh Antagonist","Hemostasis markers",{"date":244,"type":45},{"date":270,"type":45},"2025-09-30",{"date":272,"type":22},"2027-03-30",{"name":51,"class":52},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":90,"sex":18,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":300},"100494096","bleeding-of-unknown-cause-a-swiss-case-control-study-100494096","NCT05713734","Bleeding of Unknown Cause: a Swiss Case-control Study","Bleeding of Unknown Cause, Insight Into a Multifactorial Bleeding Disorder: a Swiss Case-control Study","SWISS-BUC","Inclusion Criteria:\n\n* Man with ISTH BAT\\>3. If the calculated score includes a surgical bleeding, then two other items of the score should be \\>0\n* Woman with ISTH BAT \\>5 points. If the calculated score includes a surgical or a postpartum bleeding, then two other items of the score should be \\>0\n\nExclusion Criteria:\n\n* Ongoing pregnancy\n* Intake of antithrombotic treatment or non-steroidal anti-inflammatory drugs for least 10 days at time of blood collection\n* Intake of antifibrinolytic or blood product administration (factor concentrate, frozen fresh plasma, prothrombin complex concentrate) for least 14 days before blood collection\n* Active cancer (defined as cancer diagnosis within the last five years or treatment within the two last years before study inclusion)\n* Active autoimmune disease\n* Active chronic inflammatory disease\n* Severe liver disease (cirrhosis \\> Child A)\n* Renal insufficiency stage 3\n* Active or recent infection (within the last 30 days)\n* Recent hospitalization (\\\u003C3 months)\n* Recent surgery (\\\u003C3 months)\n* Recent trauma requiring medical intervention (\\\u003C3 months)","16 Years","65 Years",{"count":285,"type":22},400,"The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.",[148],[289,290,291,292,293],"Bleeding","Hemostatics","Fibrin","Fibrinolysis","Thrombin",{"date":244,"type":45},{"date":296,"type":45},"2023-04-01",{"date":298,"type":22},"2027-04-01",{"name":51,"class":52},7,{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":53},"100633788","transcranial-temporal-interference-stimulation-ttis-to-modulate-essential-tremor-100633788","NCT07531238","Transcranial Temporal Interference Stimulation (tTIS) To Modulate Essential Tremor","Transcranial Temporal Interference Stimulation (tTIS) To Modulate Essential Tremor: A Single-Center, Proof-of-Concept Study (TremorTIS (Pilot))","TremorTIS","Inclusion Criteria (for both arms):\n\n* Informed Consent signed by the subject;\n* Age ≥ 18 years;\n* Diagnosis of Essential Tremor (ET) based on the proposed criteria by the Movement Disorders Society;\n* Candidate for MRgHIFU thalamotomy\n\nExclusion Criteria (for both arms):\n\n* Unable to provide informed consent;\n* Severe sensory or cognitive impairment or musculoskeletal dysfunction that prohibits understanding instructions or performing the experimental tasks.\n\nOnly for patients undergoing the tTIS protocol (experimental arm):\n\n* Severe neuropsychiatric (e.g., major depression, severe dementia, psychosis) or unstable systemic diseases (e.g., severe progressive and unstable cancer, life-threatening infectious disease);\n* Inability to follow or non-compliance with the procedures of the study;\n* Contraindications for non-invasive brain stimulation:\n\n  * Electronic or ferromagnetic medical implants or devices\n  * History of seizures",{"count":310,"type":22},6,[25],"The goal of this proof-of-concept study is to examine the effects of a relatively new, non-invasive electrical current-based technique, transcranial temporal interference stimulation (tTIS), in patients with Essential Tremor (ET). TTIS is delivered via a Digitimer Ltd. stimulator, the \"DS5 Isolated Bipolar Constant Current Stimulator.\" The method enables targeting deep cerebral structures to selectively modulate neurons. The structure of interest in the present study is the ventralis intermedius (VIM) of the thalamus, which plays a key role in tremor generation in people with essential tremor. Therefore, techniques targeting the VIM nucleus can potentially improve the tremor and the quality of life in the long term, as is the case with MRI-guided high-intensity focused ultrasound (MRgHIFU). Despite its efficiency, MRgHIFU can lead to side effects that could benefit from improved predictive modeling. In our proof-of-concept study, the investigators aim to examine whether tTIS of the VIM nucleus can alter tremor characteristics and, therefore, mimic the effects of MRgHIFU. This work would pave the way for future clinical trials to design prediction tools for MRgHIFU if the investigators can demonstrate the positive impact of tTIS.",[314],"Essential Tremor",[316,317,314,318],"Transcranial temporal interference stimulation","Neuromodulation","Nucleus ventralis intermedius","2026-04-27",{"date":321,"type":45},"2026-05-01",{"date":323,"type":22},"2026-05-26",{"date":325,"type":22},"2027-05",{"name":51,"class":52},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":90,"sex":113,"minAge":142,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":357},"100635232","digital-telecytology-for-triage-of-hpv-positive-women-in-cameroon-100635232","NCT07550010","Digital Telecytology for Triage of HPV-Positive Women in Cameroon","Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day \"Test-triage-treat\" Cervical Cancer Screening Strategy in Cameroon","Inclusion Criteria:\n\n* HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old\n* Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).\n\nExclusion Criteria:\n\n* Pregnancy at the time of screening\n* Previous hysterectomy\n* Known cervical cancer\n* Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)\n* Conditions that can interfere with visualization of the cervix\n* Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure)\n* Women who are not able to comply with the study protocol.","50 Years",{"count":336,"type":22},1800,[25],"This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings",[340,341,342],"Human Papillomavirus Infection","Cervical Intraepithelial Neoplasia Grade 2 (CIN2)","Cervical Cancer Screening Methods",[344,345,346,347,348],"HPV self-sampling","Telecytology","Artificial intelligence","Extended HPV genotyping","Low-resource settings","2026-04-17",{"date":351,"type":45},"2026-04-24",{"date":353,"type":45},"2025-09-08",{"date":355,"type":22},"2027-09-08",{"name":51,"class":52},2,{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":368,"studyType":94,"phases":4,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":385,"locationsCount":53},"100631874","investigation-of-gastric-emptying-by-gastric-ultrasonography-in-diabetic-patients-treated-with-glp-1-receptors-100631874","NCT07506356","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors","Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors Agonists","SAGUSE","Inclusion Criteria:\n\n* Female\u002F Male of 18 years old or more\n* With Type 2 Diabetes\n* Treated with GLP 1 analog for more than 3 months\n* Signed consent\n* ASA between I and IV\n\nExclusion Criteria:\n\n* Insuline treatment\n* Gastro intestinal motility disorders\n* Past gastric surgery\n* Hiatal hernia\n* Recent trauma\n* Inability to be lay down for the exam\n* Inability to follow the instructions for the exam (language, dementia)\n* BMI \\> 40\n* Inability to stop smoking 12h before the measures",{"count":367,"type":22},38,"7 Days","Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach.\n\nThis is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days.\n\nTo recruit the necessary number of participants, approximately 1.5 years will be needed.\n\nThis project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project.\n\nThe project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and\u002For cereals and\u002For proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam.\n\nAt 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.",[371,372,373],"Diabete Type 2","Regurgitation","Pulmonary Aspiration During Anaesthetic Induction",[375,376,377,378,379,380],"GLP-1 agonists","GLP-1 analog","Diabetes","Gastric ultrasound","Anesthesia","GUS","2026-03-27",{"date":47,"type":45},{"date":47,"type":22},{"date":104,"type":22},{"name":51,"class":52},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":90,"sex":113,"minAge":19,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":53},"100394720","impact-of-a-mindfulness-intervention-on-infertile-women-undergoing-assisted-reproductive-technique-treatments-100394720","NCT04419740","Impact of a Mindfulness Intervention on Infertile Women Undergoing Assisted Reproductive Technique Treatments","What is the Impact of an E-tool Based Mindfulness Intervention on Psychological Outcomes Compared to no Intervention in Infertile Women Undergoing Assisted Reproductive Technique Treatments: A Randomized Controlled Study?","EMOT-IVF","Inclusion Criteria:\n\nParticipants fulfilling all of the following inclusion criteria are eligible for the study:\n\n* French-speaking\n* Women between the ages of 18-42 years\n* Scheduled for the first IVF treatment in HUG\u002FCHUV\u002FCPMA Lausanne\n* Access to a computer\u002Fsmartphone\u002Ftablet with access to internet and a valid Email address\n* Informed Consent as documented by her signature on the form (Appendix Informed Consent Form)\n\nExclusion Criteria:\n\n* Psychotropic medication\n* Ongoing psychiatric\u002Fpsychological treatment\n* Known severe psychiatric co-morbidity","42 Years",{"count":63,"type":22},[25],"Infertility and its treatments can have a significant impact on women's psychological health. Anxiety has a negative impact on quality of life during treatment and can lead to withdrawal of care. the investigators would like to test the effectiveness of an application available via the Internet that offers daily exercises such as mindfulness meditation. Women in the \"treatment\" group will be instructed to practice meditation exercises using the 15-minute daily application during in vitro fertilization treatment until pregnancy testing. Women in the control group will have the standard care of the centre. The investigators will measure the effectiveness of the intervention on anxiety, depression, quality of life and mindfulness aspects. The investigators will also assess the impact on the chances of pregnancy and stress.",[399],"Infertility, Female","2026-03-25",{"date":381,"type":45},{"date":403,"type":45},"2021-10-01",{"date":104,"type":22},{"name":51,"class":52},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":357},"100528651","middle-meningeal-artery-embolization-for-chronic-subdural-hematomas-stormm-100528651","NCT06163547","Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)","Middle Meningeal Artery (MMA) Embolization for cSDH: Rationale and Design for the STOp Recurrence of MMA Bleeding (STORMM) Randomized-Control Trial","STORMM","Inclusion Criteria:\n\n* Age: 18-100\n* Consent possible\n* cSDH located at the convexities\n* Patients with symptomatic cSDH\n* Patients with asymptomatic large chronic\u002Fsubacute hematoma after 6 weeks of failed conservative treatment\n\nExclusion Criteria:\n\n* Consent not possible\n* Pregnancy\n* Prisoner\n* Angiography contraindication\n* Patient for whom follow-up is problematic (e.g. distant residency, homeless …)\n* Previous surgery for cSDH","100 Years",{"count":416,"type":22},180,[25],"Chronic Subdural Hematomas (cSHD) are common, and due to cerebral compression, often result in neurological impairment and reduced consciousness. Surgery is typically performed once neurological symptoms develop. Recent studies suggest that arteries nourished by the middle meningeal artery (MMA) may be responsible for hematoma progression and that MMA embolization is clinically useful. There is less evidence, that embolization of MMA also may be a treatment option for individuals without surgical treatment. The investigators propose a multicentre study to investigate both potentials: (1) Assessment of efficacy of embolization after surgery to reduce recurrence and improve outcomes by conducting a randomized trial (randomization arms; Arms 1 and 2), (2) Assessment of embolization-alone efficacy when surgery is contraindicated or refused (embolization-only arm, Arms 3 and 4).",[420,421],"Chronic Subdural Hematomas","Cerebral Compression Due to Injury","2026-03-16",{"date":424,"type":45},"2026-03-17",{"date":426,"type":45},"2025-02-18",{"date":428,"type":22},"2027-01-01",{"name":51,"class":52},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":53},"100541893","mental-imagery-and-targeted-memory-reactivation-in-insomnia-100541893","NCT06335784","Mental Imagery and Targeted Memory Reactivation in Insomnia","Inclusion Criteria:\n\n* Age between 18 and 45 years\n* Insomnia disorder according to the International Classification of Diseases 3 (ICSD-3)\n* ISI \\> 10\n* PSQI \\> 5\n* No other current treatment for Insomnia\n\nExclusion Criteria:\n\n* patients with another psychiatric disorder requiring acute treatment according to DSM-5\n* patients with medical (e.g. neurological disorders) or other disorders explaining the predominant complaint of insomnia (e.g., sleep apneas with ODI\\>15\u002Fh, restless legs syndrome, periodic limb movements with PLM\\>15, chronic pain)\n* patients with significant substance use\u002Fwithdrawal\n* patients with heavy smoking\n* known pregnancy\n* patients suffering from anosmia, olfactory related issues and respiratory pathology","45 Years",{"count":438,"type":22},120,[25],"In this clinical trial, the investigators test whether mental Imagery Rescripting (IR), a technique where the individual is instructed to transform a negative memory or image into a positive one, and olfactory Targeted Memory Reactivation (TMR), a technique used to strengthen memories, can reduce hyperarousal and insomnia severity in patients with Insomnia Disorder (ID).\n\nPatients with ID will be randomized into four groups: in the first group (SH group), patients will have 4 weekly sessions (1 session\u002Fweek) of a minimal intervention for insomnia (sleep hygiene information) in the presence of an odorless diffuser, which will be also used during the night. In the second group (IR group), patients will use IR during wakefulness to induce a state of relaxation and positive emotionality. More specifically, during 4 weekly sessions of IR, patients will imagine a negative scenario related to their pre-sleep images or current concerns (e.g., social interactions, self-image, sleep problem, nightmares) and transform it into a positive script. They will then perform IR every day for 4 weeks at home in the presence of an odorless diffuser, which will be also used during the night. In the third group, patients will undergo the same 4 weekly IR sessions and an odor will be paired to the positive imagery and will be diffused during the night (TMR group). Patients from this group will also perform IR every day for 4 weeks at home. Finally, the fourth group (OA group) will receive 4 weekly sessions of sleep hygiene instructions in the presence of an odor, which will be also used during the night.\n\nClinical evaluation of insomnia severity before and after the intervention will take place using the Insomnia Severity Index (ISI, primary outcome measure).\n\nAt the end of these interventions, patients with persistent symptoms will benefit from an alternative experimental treatment (\"rocking bed\") in which they will be cradled for one night.\n\nThe investigators hypothesize that patients treated with IR will have significantly reduced insomnia severity compared to participants who received a minimal intervention. They also hypothesize that patients of the TMR group, will have more reduced ID severity compared to participants performing IR and with an odorless diffuser, therefore without an association (IR group). Finally, they hypothesize that one night of sleeping in a rocking bed will improve objective measures of sleep in ID compared to a stationary condition.",[442],"Insomnia Disorder",[444,445,446,447],"Insomnia","Odors","Imagery","TMR","2026-03-02",{"date":450,"type":45},"2026-03-03",{"date":452,"type":45},"2024-04-22",{"date":454,"type":22},"2027-08-31",{"name":51,"class":52},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":53},"100626807","home-based-physiotherapy-in-oncology-100626807","NCT07440433","Home-Based Physiotherapy in Oncology","Home-Based Physiotherapy for Oncology Patients: Feasibility and Acceptability of a Supervised Exercise Programme","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of solid cancer, undergoing or recently completed treatment.\n* Overall survival greater than 12 months, as judged by the treating oncologist\n* Clinically stable and deemed fit for moderate exercise by the treating oncologist\n* Able to use an exercise bike\n* Home environment suitable for delivery and installation of the exercise bike\n* Able to understand the study language and follow study instructions\n* Able to give a written informed consent\n\nExclusion Criteria:\n\n* Medical contraindication to moderate exercise (e.g. uncontrolled cardiac or pulmonary disease, recent myocardial infarction, severe anemia or acute infection, unstable bone metastases or high fracture risk)\n* Cognitive impairment preventing active participation\n* Physical inability to perform the prescribed exercise programme, including cycling and resistance exercises.\n* Participation in another intensive rehabilitation program\n* Any other condition that, in the opinion of the treating oncologist or investigator, makes participation unsafe or not feasible\n* Pregnant or lactating women.",{"count":464,"type":22},21,[25],"The goal of this clinical trial is to assess the feasibility, acceptability, and safety of a supervised home-based physiotherapy programme for adult oncology patients. The programme combines aerobic cycling exercise, resistance training, and mental preparation strategies, delivered at home with regular professional supervision.\n\nThe main questions this study aims to answer are:\n\nIs a 6-month supervised home-based physiotherapy programme feasible in terms of recruitment, adherence, and retention?\n\nIs the programme safe for oncology patients undergoing or having recently completed cancer treatment?\n\nIs the programme acceptable and satisfactory from the patient's perspective?\n\nHow do physical function and health-related quality of life change over the course of the programme?\n\nThis is a single-arm feasibility study with no comparison group.\n\nParticipants will:\n\nReceive a stationary exercise bike delivered and installed at their home\n\nFollow a 6-month individualized physiotherapy programme including:\n\nThree weekly sessions combining moderate-intensity cycling and resistance exercises\n\nWear a connected activity watch during exercise sessions to monitor heart rate and exercise duration\n\nReceive weekly supervision from oncology-trained physiotherapists through alternating in-person hospital visits and structured phone calls\n\nComplete physical function assessments and questionnaires on quality of life, fatigue, and programme satisfaction at baseline, mid-program, and study completion\n\nThe results of this study will inform the design of a future larger controlled trial and contribute to the development of accessible home-based rehabilitation programmes for oncology patients.",[468,469],"Rehabilitation Exercise","Oncologic Diseases","2026-02-25",{"date":472,"type":45},"2026-02-27",{"date":474,"type":22},"2026-03",{"date":476,"type":22},"2028-03",{"name":51,"class":52},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":53},"100624023","neural-correlates-of-motor-and-psychiatric-fluctuations-in-parkinsons-disease-100624023","NCT07404241","Neural Correlates of Motor and Psychiatric Fluctuations in Parkinson's Disease","Subthalamic and Cortical Electrophysiological Correlates of Motor and Neuropsychiatric Fluctuations in Parkinson's Disease","Transition STN","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease (PD) based on United Kingdom Parkinson's Disease Society Brain Bank Criteria.\n* Patients candidate for STN-DBS in the PD phase called fluctuations stage.\n* Presence of fluctuations (motor and\u002For non-motor) are based on the pre-surgical DBS assessment:\n* To be on dopaminergic therapy.\n* Patients who have undergone STN-DBS implantation within 4 to 8 weeks before electrophysiological acquisition.\n\nExclusion Criteria:\n\n* Patients with an age greater than 80 years,\n* Dementia (defined by a MOCA score ≤24),\n* Active psychosis or depression with suicidal ideation,\n* Any clinically meaningful non-stable physical diseases,\n* Patients with OFF-drug state so severe that it prevents study tests from being carried out (e.g acute painful dystonia, intolerable non-motor symptoms such as pain, anxiety),\n* Participating in a pharmacological study,\n* Inability to provide informed consent (legal guardianship).","80 Years",{"count":258,"type":22},"This study explores the electrophysiological mechanisms underlying motor and non-motor fluctuations (NMF) in Parkinson's disease (PD), focusing on cortical and subthalamic dynamics during acute dopaminergic stimulation.\n\nPD is characterized by both motor symptoms and disabling non-motor symptoms-including neuropsychiatric fluctuations that remain poorly understood. While local field potentials (LFP) recorded from the subthalamic nucleus (STN) via deep brain stimulation (DBS) have revealed beta-band abnormalities linked to motor dysfunction, little is known about the oscillatory signatures of NMF. Preliminary data from our group suggested that gamma-band EEG activity in frontotemporal regions may correlate with neuropsychiatric fluctuations.\n\nThis Swiss, two-center, prospective observational study aims to investigate resting-state electroencephalogram (EEG) and STN-LFP correlates of motor and non-motor symptoms during a modified levodopa challenge in 30 PD patients with STN-DBS. Using high-density EEG and chronically implanted Medtronic Percept™ DBS devices, electrophysiological data will be collected across five clinical states (combinations of ON\u002FOFF levodopa and DBS). Clinical symptoms will be assessed alongside electrophysiological activity to identify frequency-specific cortical-STN biomarkers. Machine learning models (e.g., LASSO regression) will be used to predict motor and non-motor states from EEG and LFP data, enabling the identification of dynamic oscillatory markers. This could inform future adaptive DBS strategies.\n\nThe study leverages advanced methods in neurophysiology, imaging, and machine learning to deepen our understanding of PD fluctuations. It also proposes the first detailed electrophysiological mapping of NMF, which could improve patient stratification and neuromodulation therapies. Anatomical validation of DBS lead placement will be performed using standard neuroimaging toolkits.",[490],"PARKINSON DISEASE (Disorder)",[492,493,494,495,496,497],"neuropsychiatric fluctuations","non-motor symptoms","Local field potentials","Electroencephalography","Deep brain stimulation","Subthalamic nucleus","2026-02-04",{"date":500,"type":45},"2026-02-11",{"date":502,"type":45},"2025-06-01",{"date":504,"type":22},"2028-12-31",{"name":51,"class":52},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":113,"minAge":436,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":53},"100581859","time-restricted-eating-in-menopause-and-hormone-sensitive-breast-cancers-tremho-100581859","NCT06855784","Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)","Time-Restricted Eating to Improve Body Composition and Symptoms in Menopause and HOrmone-sensitive Breast Cancers (TREMHO) - An Open-label Randomized Controlled Trial","TREMHO","Inclusion Criteria:\n\n* Women with confirmed physiological menopause without current anti-cancer treatment (group A), or women with menopausal symptoms in the context of aromatase inhibitors used as adjuvant therapy for hormone-sensitive non-metastatic breast cancers regardless of physiological menopause before the cancer diagnosis (group B)\n* Age 40-65 years\n* Body mass index 25-40 kg\u002Fm2\n* Stable weight (± 2 kg) over the previous month\n* Eating window ≥ 12 hours (self-reported and measured during the run-in phase)\n* Able to give informed consent and follow the study procedures for the entire duration\n* Confident use of a smartphone and able to take regular pictures of food\u002Fdrinks\n\nExclusion Criteria:\n\n* On a hypocaloric restrictive diet, intermittent fasting or in a weight management program over the previous month\n* Previous bariatric surgery or planned during the study\n* Active eating disorder(s) or major mental illness at inclusion\n* Psychoactive treatment with recent or planned changes of drug compound or dosage\n* Treatments affecting body weight (e.g. glucocorticoids, GLP-1 receptor analogues)\n* Diabetes with hypoglycemic drug(s) will be excluded, however those with prediabetes (as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included\n* Active metabolic bone diseases (e.g. Paget disease, osteomalacia), however women with osteoporosis will be included\n* Shift work comprising night shifts (working between 11pm and 6am) over the previous 2 weeks or planned during the study\n* Travel\u002Ftrip to a different time zone (≥ 2-hour time difference) over the previous 2 weeks or planned during the study\n* Enrolled in another interventional clinical trial (medication, surgery, medical device) over the previous 2 weeks or planned during the study","60 Years",{"count":516,"type":22},84,[25],"This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context.\n\nIn this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating \\[TRE\\] 16h\u002F8h). In the control group, the usual eating pattern is continued for 12 weeks.\n\nThe main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.",[520,521],"Menopause","Obesity and Overweight","2026-01-23",{"date":524,"type":45},"2026-01-27",{"date":526,"type":45},"2025-04-30",{"date":528,"type":22},"2027-03-01",{"name":51,"class":52},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":142,"studyType":94,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":551},"100479697","neurist--intregrated-biomedical-informatics-for-the-management-of-cerebral-aneurysms-100479697","NCT05526352","@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms","@neurIST : Informatique biomédicale intégrée Pour la Gestion Des anévrismes cérébraux","@neurIST","Inclusion Criteria:\n\n* able to provide consent or, in the event that a patient is incapable of providing consent, that a person is legally authorized to do so on behalf of the patient according to legal and ethical requirements of the country where the clinical centre is located.\n\nPatients:\n\n* must have an angiographically proven intracranial aneurysm (MRA\\\u003C CTA\\\u003C DSA accepted).The determination of SAH requires the presence of a subarachnoid haemorrhage be verified on CT or by lumbar puncture.\n\nMRA: Magnetic Resonance Angiography CTA: Computed Tomography Angiography DSA: Digital Subtracted Angiography\n\nExclusion Criteria:\n\n* failure of a candidate to contribute clinical data,\n* refusal to provide informed consent.",{"count":539,"type":22},20000,"The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA).\n\nThe SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database.\n\nThe purpose for populating the database are to:\n\n* Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as markers the following: genetics factors, microbiota, environmental factors, congenital factors (ie: cerebrovascular anatomical variants), transcriptomics signature, proteomics signature,shape characteristics, haemodynamics characteristics.\n* Screen for and evaluate prognostic factors of outcome regarding different management strategies including watchful observation, microsurgical treatment, endovascular treatment or any combination thereof.\n* Implement and evaluate patient-specific management protocols integrating all available information.\n* Evaluate the impact of the database and use of tools to improve care, reduce costs, support knowledge discovery and promote new industrial developments.",[542],"Intracranial Aneurysm","2026-01-14",{"date":545,"type":45},"2026-01-16",{"date":547,"type":45},"2015-06-01",{"date":549,"type":22},"2040-03-01",{"name":51,"class":52},22,{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":90,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":560,"conditions":561,"keywords":566,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":53},"100617470","breathlessness-patterns-in-patients-with-cancer-copd-and-heart-failure-an-fmri-feasibility-study-100617470","NCT07319039","Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study","BREACH-fMRI","Inclusion Criteria\n\n* Age ≥ 18 years and\n* Followed by the outpatient palliative care clinic of the Geneva University Hospitals, Switzerland (HUG) and\n* Breathlessness at rest \\> 2 and \\\u003C 8 on the NRS (numeric rating scale 0 to 10) and\n* Persistent breathlessness (persistent dyspnea for \\> 3 weeks despite adequate and maximal medication according to the pathology) and\n* In a stable clinical condition, i.e., without an episode of acute cardiac, respiratory, and\u002For neurological failure leading to hospitalization in the previous 4 weeks and\n* Diagnosis of either HF stage NYHA III-IV, or COPD with dyspnea on the modified MRC scale grade 3-4, or oncological disease with primary or secondary pulmonary involvement\n\nInclusion Criteria for Healthy Volunteers (Control Group)\n\n* Age ≥ 18 years and\n* No respiratory symptoms: dyspnea, cough, wheezing and\n* No known pulmonary, cardiac, or oncological disease and\n* Smoking status \\\u003C 10 pack-years and\n* No contraindication to fMRI (Appendix 3) and\n* Ability to lie flat (supine position) and\n* No diagnosed psychiatric illness (severe depression, severe anxiety, psychosis, other) or antipsychotic treatment deemed a contraindication for fMRI based on physician judgement and\n* No neurological disorders according to neurological assessment, including diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.), or epilepsy and\n* No claustrophobia, acrophobia, photophobia, severe hearing loss, and\u002For severe visual deficit and\n* No contraindication to IVR (migraines, photosensitive epilepsy, vertigo)\n\nExclusion Criteria\n\n* Breathlessness at rest ≥ 8 on the NRS (numeric rating scale 0 to 10)\n* Contraindication to fMRI\n* Inability to lie flat (supine position)\n* Diagnosed psychiatric illness (severe depression, severe anxiety, psychosis, other) or antipsychotic treatment deemed a contraindication for fMRI based on physician judgement\n* Neurological disorders according to neurological assessment, including diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.), or epilepsy\n* Presence of claustrophobia, acrophobia, photophobia, severe hearing loss, and\u002For severe visual deficit\n* Contraindication to IVR (migraines, photosensitive epilepsy, vertigo)",{"count":115,"type":22},"Dyspnea that persists despite optimal pathophysiological treatment is defined as persistent dyspnea.\n\nCurrently all brain functional magnetic resonance imaging (fMRI) studies conducted to evaluate breathlessness have done so using healthy volunteers or have concentrated on acute breathlessness. Little is known about chronic breathlessness patterns and their modulation by different triggers. Furthermore, it is currently assumed in the palliative care literature that patients suffering from different advanced and progressive diseases such as cancer, heart failure (HF) or chronic obstructive pulmonary disease (COPD) have the same triggers, perceptions and neurological pathways and thus require the same treatments\u002Finterventions (i.e. opioids as first line symptomatic pharmacologic treatment). However, it is now known that patients belonging to different disease groups do not necessarily benefit from opioids.\n\nAim of the study To assess the feasibility of identifying dyspnea patterns in different life-limiting conditions and to evaluate the effect of immersive virtual reality (IVR) on dyspnea using patient-reported-outcomes (PROMs).\n\nStudy procedure:\n\nPatients with advanced chronic diseases such as cancer, COPD or HF suffering from dyspnea will undergo a brain fMRI in combination with an IVR intervention. The fMRI data will be reviewed to identify different patterns of dyspnea and the effect of IVR on dyspnea will be assessed through PROMs. Patients will be asked about the perceived burden of the study.",[562,563,564,565],"Chronic Obstructive Pulmonary Disease (COPD)","Heart Failure","Cancer","Volunteers",[567,568,569,570,571],"Persistent dyspnea","Breathlessness","Palliative Medicine","Cerebral fMRI","Immersive virtual reality","2026-01-06",{"date":574,"type":45},"2026-01-08",{"date":576,"type":45},"2025-08-26",{"date":528,"type":22},{"name":51,"class":52},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":113,"minAge":586,"maxAge":142,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":594,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":53},"100617594","improving-shared-decision-making-in-menstrual-management-and-contraception-for-adolescents-and-young-adults-100617594","NCT07320651","Improving Shared Decision-Making in Menstrual Management and Contraception for Adolescents and Young Adults","Improving Shared Decision-Making in Menstrual Management and Contraception for Adolescents and Young Adults: A Cluster-Randomized Trial","Inclusion Criteria:\n\n* adolescents and young adults aged 12-25 years old\n* presenting to an outpatient consultation at \"Unité de policlinique de gynécologie\" or \"Consultation de gynécologie pédiatrique\" at HUG\n* considering initiation or switch to hormonal medication for menstrual management and\u002For contraception\n* able to give informed consent as documented by signature or accompanied by a legal guardian who can provide consent if required.\n\nExclusion Criteria:\n\n* individuals who cannot read and understand French to a degree that would prevent participation in informed consent and study-related materials.\n* individuals who have major sensory disability, such as visual or hearing impairment, that would compromise their ability to give written informed consent and use the EDA, in the absence of their legal guardian.\n* individuals with cognitive or psychiatric conditions significantly impairing decision making capacity, unless accompanied by a legal guardian.\n* patients currently participating in another clinical trial related to contraceptive decision-making, to avoid potential interference.","12 Years",{"count":588,"type":22},252,[25],"Decision aids are educational tools designed to help people participate in decision-making about health care choices, by providing evidence-based information, promoting patient-centered care, and supporting patient autonomy and engagement. Our research team developed an Encounter Decision Aid (EDA) exploring treatment options for menstrual management in adolescents and young adults (AYAs), in accordance with the latest International Patient Decision Aids Standards and the Ottawa Decision Support Framework.\n\nIn this cluster-randomized controlled trial, we aim to evaluate the effectiveness of this EDA on patient-centered outcome measures in AYAs considering treatment for menstrual management and\u002For contraception compared to standard counseling.",[592,593],"Contraception","Menstrual Management",[595,154,153,596],"decision aid","shared decision-making","2025-12-25",{"date":572,"type":45},{"date":600,"type":45},"2025-09-02",{"date":602,"type":22},"2028-01",{"name":51,"class":52},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":334,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":357},"100563646","incremental-diagnostic-value-of-tau-pet-with-18fro948-vs-amyloid-pet-in-patients-with-cognitive-impairment-100563646","NCT06618872","Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment","Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With","IDV of tau-PET","Inclusion Criteria:\n\n* Written Inform Consent to participating.\n* 50 to 85 years of age\n* a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments)\n* availability of MRI within 6 months before screening\n* prescription of a diagnostic amyloid PET\n* Willing and able to comply with the requirements of the study, as judged by the investigator.\n\nExclusion Criteria:\n\n* The presence of psychiatric disorders, extensive white matter lesions or other stigmata of vascular dementia.\n* Visual and auditory acuity inadequate for neuropsychological testing.\n* Enrolment in previous clinical trials for AD potentially affecting amyloid and\u002For tau brain load\n* Enrolment in other trials or studies not compatible with \\[18F\\]RO948 Imaging study.\n* Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning.\n* Women of childbearing potential must not be pregnant (negative urine β-hCG on the day of imaging) or breast feeding at screening","85 Years",{"count":438,"type":22},[25],"The objective of the study is to investigate the clinical validity of tau-PET with \\[18F\\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia",[617,618],"Dementia","Alzheimer Disease",[620,621,622,623],"Alzheimer","PET","Amyloid","Tau","2025-12-16",{"date":626,"type":45},"2025-12-23",{"date":628,"type":45},"2024-12-03",{"date":630,"type":22},"2027-08-30",{"name":51,"class":52},{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":90,"sex":113,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":647,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":53},"100603504","assessing-the-impact-of-therapeutic-communication-on-patients-anxiety-during-elective-cesarean-sections-100603504","NCT07137377","Assessing the Impact of Therapeutic Communication on Patients' Anxiety During Elective Cesarean Sections","CESARCOM Study Protocol: Assessing the Impact of Therapeutic Communication on Patients' Anxiety During Elective Cesarean Sections, - a Before-and-after Interventional Study","CESARCOM","Inclusion Criteria:\n\n-≥18 years\n\n* elective c-section planned in the Maternity Unit of the Geneva University Hospitals\n* consent to participate\n\nExclusion Criteria:\n\n* Not-French-speaking patients (interpreter required).\n* All emergency c-sections.\n* Death during the intervention.",{"count":641,"type":22},260,[25],"Background:\n\nAnxiety is highly prevalent before elective caesarean sections and can have a negative impact on anesthetic outcomes, postoperative pain and maternal mental health. The use of pharmacological premedication is controversial, and non-pharmacological alternatives are increasingly being explored. Therapeutic communication, based on empathy, positive language and the conscious avoidance of negative or anxiety-inducing suggestions, has shown promise in other surgical settings. However, its effectiveness in obstetrics remains to be explored.\n\nMethods This is a single-centre, prospective, observational, before-and-after study. The study aims to assess whether implementing an on-line (asynchronous) training programme on therapeutic communication for obstetric care teams can reduce maternal anxiety following elective caesarean sections. The study includes two groups of 130 patients each, one before the intervention and one after. Anxiety levels will be assessed using the French version of the State-Trait Anxiety Inventory score, and the primary outcome will be the difference in scores after caesarean section between the two groups. Secondary outcomes include the proportion of patients with high anxiety levels (STAI-State score \\>45), as well as staff satisfaction, feeling of relevance, and indicators of the feasibility of implementing the training.\n\nThe intervention consists of a short (less than 1 hour) training course using podcasts and flashcards, combined with distributing a lexicon that promotes hypnosis-based therapeutic communication (HBTC). Staff participation, perceived relevance and satisfaction will be assessed using structured questionnaires based on the Likert scale.\n\nLinear and logistic regression analyses will be used to adjust for confounding variables, including baseline anxiety, psychiatric history, and intraoperative complications.\n\nDiscussion This is the first study to evaluate the impact of a dedicated HBTC training programme on patient anxiety and staff experience in an obstetric surgical setting. By integrating this approach into routine cesarean section care, our aim is to improve the patient experience and enhance communication practices within clinical teams. The results could inform clinical practices on non-pharmacological strategies in obstetric care.",[645,646],"Communication","Anxiety",[648,649,650],"hypnosis based therapeutic communication","anxiety","STAI score","2025-08-20",{"date":653,"type":45},"2025-08-22",{"date":655,"type":45},"2025-04-14",{"date":657,"type":22},"2027-07-31",{"name":51,"class":52},{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":91,"enrollmentInfo":667,"targetDuration":669,"studyType":94,"phases":4,"briefSummary":670,"conditions":671,"keywords":674,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":53},"100602910","cholangitis-definition-and-treatment-after-kasai-hepatoportoenterostomy-for-biliary-atresia-track-ba-study-tracking-cholangitis-post-kasai-in-biliary-atresia-100602910","NCT07129655","Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Cholangitis Post Kasai in Biliary Atresia)","Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: a Feasibility Study","TRACK-BA","Inclusion Criteria:\n\n* patients with a suspected diagnosis cholangitis within 1 year after Kasai hepatoportoenterostomy\n\nExclusion Criteria:\n\n* recurrent cholangitis, cholangitis \\>1 year after Kasai",{"count":668,"type":22},40,"1 Year","Biliary atresia is a rare liver disease affecting newborns. In those babies bile ducts are blocked, and bile cannot flow from the liver to the intestines. Biliary atresia patients require a special surgery called \"Kasai operation\" to restore the bile flow. A common and serious problem after surgery is an infection of the bile ducts, called cholangitis, which can damage the liver and lead an earlier need for liver transplantation.\n\nIn 2022, a group of international experts led by the Swiss Pediatric Liver Center from the HUG created new guidelines to help identify and treat cholangitis more consistently.\n\nThis study will test how well these new definitions work in real life of hospitals. Over one year, physicians will collect data on children in whom they suspect cholangitis in the first year after their Kasai. The goal is to see whether these new definitions are applicable in the clinical setting.\n\nThe study will involve around 40 patients and will use secure methods to store data. The findings will help improve how cholangitis is diagnosed and treated, making care more effective and consistent for children with biliary atresia.",[672,673],"Biliary Atresia, Kasai Portoenterostomy Status","Cholangitis",[675,676,677],"biliary atresia","Kasai hepatoportoenterostomy","acute cholangitis","2025-08-11",{"date":680,"type":45},"2025-08-19",{"date":682,"type":22},"2025-10-01",{"date":684,"type":22},"2026-09-30",{"name":51,"class":52},""]